Next Article in Journal
Xylan Decomposition in Plant Cell Walls as an Inducer of Surfactin Synthesis by Bacillus subtilis
Next Article in Special Issue
Discovery and Characterization of an ALFA-Tag-Specific Affinity Resin Optimized for Protein Purification at Low Temperatures in Physiological Buffer
Previous Article in Journal
Bone Health in Aging Men: Does Zinc and Cuprum Level Matter?
Previous Article in Special Issue
Nanobody-Based Indirect Competitive ELISA for Sensitive Detection of 19-Nortestosterone in Animal Urine

The Application of Nanobody in CAR-T Therapy

Shenzhen Pregene Biopharma Company Ltd., Shenzhen 518118, China
Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou 450008, China
Department of Immunology, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang 453000, China
Author to whom correspondence should be addressed.
Academic Editor: Nick Devoogdt
Biomolecules 2021, 11(2), 238;
Received: 5 December 2020 / Revised: 25 January 2021 / Accepted: 1 February 2021 / Published: 8 February 2021
(This article belongs to the Special Issue The Therapeutic and Diagnostic Potential of Nanobodies)
Chimeric antigen receptor (CAR) T therapy represents a form of immune cellular therapy with clinical efficacy and a specific target. A typical chimeric antigen receptor (CAR) construct consists of an antigen binding domain, a transmembrane domain, and a cytoplasmic domain. Nanobodies have been widely applied as the antigen binding domain of CAR-T due to their small size, optimal stability, high affinity, and manufacturing feasibility. The nanobody-based CAR structure has shown a proven function in more than ten different tumor-specific targets. After being transduced in Jurkat cells, natural killer cells, or primary T cells, the resulting nanobody-based CAR-T or CAR-NK cells demonstrate anti-tumor effects both in vitro and in vivo. Interestingly, anti-BCMA CAR-T modulated by a single nanobody or bi-valent nanobody displays comparable clinical effects with that of single-chain variable fragment (scFv)-modulated CAR-T. The application of nanobodies in CAR-T therapy has been well demonstrated from bench to bedside and displays great potential in forming advanced CAR-T for more challenging tasks. View Full-Text
Keywords: nanobody; VHH; CAR-T; BCMA nanobody; VHH; CAR-T; BCMA
Show Figures

Figure 1

MDPI and ACS Style

Bao, C.; Gao, Q.; Li, L.-L.; Han, L.; Zhang, B.; Ding, Y.; Song, Z.; Zhang, R.; Zhang, J.; Wu, X.-H. The Application of Nanobody in CAR-T Therapy. Biomolecules 2021, 11, 238.

AMA Style

Bao C, Gao Q, Li L-L, Han L, Zhang B, Ding Y, Song Z, Zhang R, Zhang J, Wu X-H. The Application of Nanobody in CAR-T Therapy. Biomolecules. 2021; 11(2):238.

Chicago/Turabian Style

Bao, Chaolemeng, Quanli Gao, Lin-Lin Li, Lu Han, Bingxiang Zhang, Yijin Ding, Zongpei Song, Ruining Zhang, Jishuai Zhang, and Xian-Hui Wu. 2021. "The Application of Nanobody in CAR-T Therapy" Biomolecules 11, no. 2: 238.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop